PTC Therapeutics (PTCT.US) enters Huntington's disease drug license agreement with Novartis (NVS.US)

Generado por agente de IAMarket Intel
lunes, 2 de diciembre de 2024, 8:30 am ET1 min de lectura
HBAN--
NVS--
PTC--
PTCT--

The stock of PTC Therapeutics (PTCT.US) rose 21% before the market opened on Monday after the company signed an exclusive global license and collaboration agreement with Novartis (NVS.US) for its Huntington's disease project PTC518.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios